Cells treated with TAP-2 antisense oligonucleotides are potents antigen-presenting cells in vitro and in vivo

Smita K. Nair, David Snyder, Eli Gilboa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Treatment of RMA and EL4 cells or freshly isolated splenocytes with antisense (AS) oligonucleotides directed against the TAP-2 gene recreates the phenotype seen in cells that are genetically deficient in TAP function. Cells incubated with AS oligonucleotides exhibit reduced MHC class I expression on the cell surface, which can be increased by incubating the oligonucleotide-treated cells at 28°C or by adding MHC haplotype-matched peptides to the culture medium. RMA cells or splenocytes treated with AS oligonucleotides and incubated with peptide were highly effective in generating primary CTL responses in vitro. The bulk of the AS oligonucleotide-responsive and CTL-inducing cells resided in the adherent fraction of splenocytes. Moreover, TAP-2 AS oligonucleotide-treated adherent splenocytes pulsed with OVA peptide elicited potent OVA-specific CTL responses in vivo and provided effective protection from challenge with tumor cells expressing the corresponding Ag. AS oligonucleotide technology provides a simple approach to develop broadly applicable methods for generating potent APC to study TAP function in normal cells and to identify other gene products involved in MHC class I presentation.

Original languageEnglish
Pages (from-to)1772-1780
Number of pages9
JournalJournal of Immunology
Volume156
Issue number5
StatePublished - Mar 1 1996
Externally publishedYes

Fingerprint

Antisense Oligonucleotides
Antigen-Presenting Cells
Peptides
In Vitro Techniques
Oligonucleotides
Haplotypes
Genes
Culture Media
Technology
Phenotype

ASJC Scopus subject areas

  • Immunology

Cite this

Cells treated with TAP-2 antisense oligonucleotides are potents antigen-presenting cells in vitro and in vivo. / Nair, Smita K.; Snyder, David; Gilboa, Eli.

In: Journal of Immunology, Vol. 156, No. 5, 01.03.1996, p. 1772-1780.

Research output: Contribution to journalArticle

@article{c2bb4e4bec914698b0e12d72762818c7,
title = "Cells treated with TAP-2 antisense oligonucleotides are potents antigen-presenting cells in vitro and in vivo",
abstract = "Treatment of RMA and EL4 cells or freshly isolated splenocytes with antisense (AS) oligonucleotides directed against the TAP-2 gene recreates the phenotype seen in cells that are genetically deficient in TAP function. Cells incubated with AS oligonucleotides exhibit reduced MHC class I expression on the cell surface, which can be increased by incubating the oligonucleotide-treated cells at 28°C or by adding MHC haplotype-matched peptides to the culture medium. RMA cells or splenocytes treated with AS oligonucleotides and incubated with peptide were highly effective in generating primary CTL responses in vitro. The bulk of the AS oligonucleotide-responsive and CTL-inducing cells resided in the adherent fraction of splenocytes. Moreover, TAP-2 AS oligonucleotide-treated adherent splenocytes pulsed with OVA peptide elicited potent OVA-specific CTL responses in vivo and provided effective protection from challenge with tumor cells expressing the corresponding Ag. AS oligonucleotide technology provides a simple approach to develop broadly applicable methods for generating potent APC to study TAP function in normal cells and to identify other gene products involved in MHC class I presentation.",
author = "Nair, {Smita K.} and David Snyder and Eli Gilboa",
year = "1996",
month = "3",
day = "1",
language = "English",
volume = "156",
pages = "1772--1780",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Cells treated with TAP-2 antisense oligonucleotides are potents antigen-presenting cells in vitro and in vivo

AU - Nair, Smita K.

AU - Snyder, David

AU - Gilboa, Eli

PY - 1996/3/1

Y1 - 1996/3/1

N2 - Treatment of RMA and EL4 cells or freshly isolated splenocytes with antisense (AS) oligonucleotides directed against the TAP-2 gene recreates the phenotype seen in cells that are genetically deficient in TAP function. Cells incubated with AS oligonucleotides exhibit reduced MHC class I expression on the cell surface, which can be increased by incubating the oligonucleotide-treated cells at 28°C or by adding MHC haplotype-matched peptides to the culture medium. RMA cells or splenocytes treated with AS oligonucleotides and incubated with peptide were highly effective in generating primary CTL responses in vitro. The bulk of the AS oligonucleotide-responsive and CTL-inducing cells resided in the adherent fraction of splenocytes. Moreover, TAP-2 AS oligonucleotide-treated adherent splenocytes pulsed with OVA peptide elicited potent OVA-specific CTL responses in vivo and provided effective protection from challenge with tumor cells expressing the corresponding Ag. AS oligonucleotide technology provides a simple approach to develop broadly applicable methods for generating potent APC to study TAP function in normal cells and to identify other gene products involved in MHC class I presentation.

AB - Treatment of RMA and EL4 cells or freshly isolated splenocytes with antisense (AS) oligonucleotides directed against the TAP-2 gene recreates the phenotype seen in cells that are genetically deficient in TAP function. Cells incubated with AS oligonucleotides exhibit reduced MHC class I expression on the cell surface, which can be increased by incubating the oligonucleotide-treated cells at 28°C or by adding MHC haplotype-matched peptides to the culture medium. RMA cells or splenocytes treated with AS oligonucleotides and incubated with peptide were highly effective in generating primary CTL responses in vitro. The bulk of the AS oligonucleotide-responsive and CTL-inducing cells resided in the adherent fraction of splenocytes. Moreover, TAP-2 AS oligonucleotide-treated adherent splenocytes pulsed with OVA peptide elicited potent OVA-specific CTL responses in vivo and provided effective protection from challenge with tumor cells expressing the corresponding Ag. AS oligonucleotide technology provides a simple approach to develop broadly applicable methods for generating potent APC to study TAP function in normal cells and to identify other gene products involved in MHC class I presentation.

UR - http://www.scopus.com/inward/record.url?scp=0030027746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030027746&partnerID=8YFLogxK

M3 - Article

VL - 156

SP - 1772

EP - 1780

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -